• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights

    11/12/24 8:02:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NVAX alert in real time by email
    • U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates
    • Achieved total revenue of $85 million in the third quarter of 2024
    • Ended the third quarter of 2024 with $1 billion in cash and receivables
    • Received authorization from U.S. FDA and European Commission for updated 2024-2025 formula COVID-19 vaccine in individuals aged 12 and older
    • Outlined R&D strategy based on its proven technology platform
    • Updates full year 2024 financial guidance
    • Company to host conference call today at 8:30 a.m. ET

    GAITHERSBURG, Md., Nov. 12, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced its financial results and operational highlights for the third quarter ended September 30, 2024.

    "Novavax continues to focus on our corporate growth strategy of driving value from additional business development activities and organic R&D using our proven technology platform," said John C. Jacobs, President and Chief Executive Officer, Novavax. "In addition to progress on our other value drivers, this past quarter, we made significant progress defining our R&D strategy as we look to expand beyond COVID-19 and influenza. We intend to develop our early-stage pipeline with a disciplined approach, as we focus on areas where our technology can have a positive impact on public health and generate value."

    Third Quarter 2024 and Recent Highlights

    During the third quarter, Novavax continued executing against its four key priorities.

    Priority #1: Successful Execution of Sanofi Partnership

    • Advanced preparation for Sanofi to assume lead commercial responsibility of Nuvaxovid™ COVID-19 vaccine for 2025-2026 vaccination season in the U.S., Europe and select major markets not currently subject to Novavax Advanced Purchase Agreements (APAs) or existing partnership agreements.
    • On track for the Novavax pediatric clinical trial database lock for the first cohort in the fourth quarter of 2024, achievement triggers a $50 million milestone payment.

    Priority #2: Drive Incremental Value from Novavax's Proven Technology Platform

    • In November 2024, the U.S. Food and Drug Administration (FDA) removed the clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. Novavax is working to initiate the Phase 3 immunogenicity clinical trial for CIC and stand-alone influenza candidates as soon as possible.
    • Signed a Matrix-M adjuvant related agreement with a leading pharmaceutical company to enable exploration of our technology for the potential advancement of their pipeline candidates.
    • Outlined guiding principles of new Research & Development (R&D) strategy based on its proven technology platform and announced the appointment of Ruxandra Draghia-Akli, MD, PhD as Executive Vice President and Head of R&D.
    • Continued to advance pandemic influenza and respiratory syncytial virus (RSV) pre-clinical programs towards IND readiness, with a focus on RSV-combination options.

    Priority #3: Continue Evolution of Novavax and Reduce Operating Expenses

    • On track with cost structure improvements, including an approximate 26% reduction in combined R&D and Selling, General and Administrative (SG&A) expenses in the third quarter of 2024 compared to the same period for 2023.
    • Targeting full year combined R&D and SG&A expenses of approximately $500 million for full year 2025 and approximately $350 million for full year 2026. A portion of these expenses are expected to be reimbursed under the Sanofi Agreement. The full year 2026 target spend reflects a reduction of approximately $1.4 billion and 80% as compared to full year 2022.

    Priority #4: Deliver an Updated COVID-19 Vaccine for the 2024-2025 Vaccination Season

    U.S. Market:

    • Received Emergency Use Authorization (EUA) from the U.S. FDA in individuals aged 12 and older.
    • Entered the market with an improved product presentation and broader access -Nuvaxovid™ available in pre-filled syringe presentation in over 30,000 locations across major pharmacy retailers and regional grocers in the U.S.
    • Novavax's COVID-19 vaccine Biologics License Application (BLA) Prescription Drug User Fee Act with an action date of April 2025 and updated to include both JN.1 variant and pre-filled syringe presentation. Achievement of BLA approval triggers a $175 million milestone payment from Sanofi.

    Global Markets:

    • Received global authorizations including in the European Union, Canada, and Taiwan.

    Third Quarter 2024 Financial Results

    • Total revenue for the third quarter of 2024 was $85 million, compared to $187 million in the same period in 2023. Product sales of $38 million for the third quarter 2024 related to primarily U.S. market commercial sales. Licensing, royalties and other revenue of $46 million in the third quarter of 2024 related to a combination of activities under the Sanofi Agreement and adjuvant sales.
    • Cost of sales for the third quarter of 2024 was $61 million, compared to $99 million in the same period in 2023. These quarters included $28 million and $74 million, respectively, related to excess, obsolete or expired inventory, losses on firm purchase commitments under third-party supply agreements and unutilized manufacturing capacity.
    • R&D expenses for the third quarter of 2024 were $87 million, compared to $106 million in the same period in 2023. The decrease was primarily due to reductions in manufacturing and clinical research-related spend.
    • SG&A expenses for the third quarter of 2024 were $71 million, compared to $107 million for the same period in 2023. The decrease was primarily due to cost reduction activities, partially offset by commercialization expenses for Nuvaxovid.
    • Net loss for the third quarter 2024 was $121 million, compared to a net loss of $131 million in the same period in 2023.
    • Cash, cash equivalents, marketable securities and restricted cash (Cash) were $924 million as of September 30, 2024, compared to $584 million as of December 31, 2023.

    Financial Framework

    Novavax is updating its Full Year 2024 Financial Guidance and expects to achieve the following objectives.

    Full Year 2024 Guidance

     

    $ in millions

    Prior

    (as of Aug. 8, 2024)

    Updated

    (as of Nov. 12, 2024)

    Total Revenue

    $700 - $800

    $650 - $700

    Product Sales 1

    $275 - $375

    $175 - $225

    Licensing, Royalties and Other Revenue 2

    $425

    $475







    Combined R&D and SG&A

    $700 - $750

    $700 - $750





    1.

    Full year 2024 product sales guidance reflects approximately $100 million in APA dose deliveries in 1H 2024 and $75 million to $125 million of commercial market sales in 2H 2024.

    2.

    Full year 2024 Licensing, royalties and other revenue guidance includes $450 million of revenue recognition from the $500 million Sanofi agreement upfront payment and $25 million in royalty and other revenue from partner-related activities.

    Conference Call

    Novavax will host its quarterly conference call today at 8:30 a.m. ET. To join the call without operator assistance, you may register and enter your phone number at https://emportal.ink/3Y6irHG to receive an instant automated call back. You may also dial direct to be entered to the call by an operator. The dial-in numbers for the conference call are (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International). Participants will be prompted to request to join the Novavax, Inc. call. A replay of the conference call will be available starting at 11:30 a.m. ET on November 12, 2024, until 11:59 p.m. ET on November 19, 2024. To access the replay by telephone, dial (888) 660-6345 (Domestic) or (+1) (646) 517-4150 (International) and use passcode 62491 #.

    A webcast of the conference call can also be accessed on the Novavax website at ir.novavax.com/events. A replay of the webcast will be available on the Novavax website until December 12, 2024.

    Trade Name in the U.S.

    The trade name Nuvaxovid has not been approved by the U.S. FDA.

    About Novavax

    Novavax, Inc. (NASDAQ:NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes CIC and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.

    Non-GAAP Financial Measures

    The Company has used a non-GAAP financial measure in this press release, which is adjusted combined R&D and SG&A expenses, net of Sanofi reimbursement costs under the Sanofi Agreement. Non-GAAP financial measures refer to financial information adjusted from financial measures prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company believes that the presentation of this adjusted financial measure is useful to investors as it provides additional information on comparisons between periods by including certain items that affect overall comparability. The Company uses this non-GAAP financial measure for business planning purposes and to consider underlying trends of its business and believes presenting this measure also provides useful information to investors and others for understanding and evaluating trends in the Company's expenses in the same manner as the Company's management. Non-GAAP financial measures should be considered in addition to, and not as an alternative for, the Company's reported results prepared in accordance with GAAP. The use of this non-GAAP financial measure may differ from similar measures reported by other companies and may not be comparable to other similarly titled measures.

    Forward-Looking Statements

    Statements herein relating to the future of Novavax, its mission; its corporate strategy and operating plans, objectives and prospects; its value drivers and near-term priorities, its partnerships, including expectations with respect to potential royalties, milestones, and cost reimbursement, and plans for additional potential partnering activities; its expectations regarding manufacturing capacity, timing, production and delivery for its COVID-19 vaccine; the development of Novavax's clinical and preclinical product candidates and innovation expansion opportunities; the conduct, timing and potential results from clinical trials and other preclinical studies; scope, timing and outcome of future and pending regulatory filings and actions, including the potential BLA approval for Novavax's COVID-19 vaccine; potential market sizes and demand for its COVID-19 vaccine and product candidates; full year 2024 financial guidance; and the amount and impact of Novavax's cost reduction plans; and Novavax's future financial or business performance.  Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, Novavax's ability to successfully and timely manufacture, market, distribute, or deliver its updated 2024-2025 formula COVID-19 vaccine and the impact of its not having received a BLA from the FDA for the 2024-2025 vaccination season; challenges related to Novavax's partnership with Sanofi and in pursuing additional partnership opportunities; challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification, assay validation and stability testing, necessary to satisfy applicable regulatory authorities; challenges or delays in conducting clinical trials or studies for its product candidates; challenges or delays in obtaining regulatory authorization for its product candidates, including for future COVID-19 variant strain changes, its CIC vaccine candidate, its stand-alone influenza vaccine candidate or other product candidates; manufacturing, distribution or export delays or challenges; Novavax's substantial dependence on Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for co-formulation and filling Novavax's COVID-19 vaccine and the impact of any delays or disruptions in their operations; difficulty obtaining scarce raw materials and supplies including for its proprietary adjuvant; resource constraints, including human capital and manufacturing capacity; constraints on Novavax's ability to pursue planned regulatory pathways, alone or with partners; challenges in implementing its global restructuring and cost reduction plan; challenges in obtaining commercial adoption and market acceptance of its updated 2024-2025 formula COVID-19 vaccine or any COVID-19 variant strain containing formulation, or for its CIC vaccine candidate and stand-alone influenza vaccine candidate or other product candidates; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities, including requirements to deliver doses that may require Novavax to refund portions of upfront and other payments previously received or result in reduced future payments pursuant to such agreements and challenges in amending or terminating such agreements; challenges related to the seasonality of vaccinations against COVID-19; challenges related to the demand for vaccinations against COVID-19 or influenza; challenges in identifying and successfully pursuing innovation expansion opportunities; Novavax's expectations as to expenses and cash needs may prove not to be correct for reasons such as changes in plans or actual events being different than its assumptions; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

     

    NOVAVAX, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except per share information)





    Three Months Ended



    Nine Months Ended



    September 30,



    September 30,



    2024



    2023



    2024



    2023





    (unaudited)



    (unaudited)

















    Revenue:

















       Product sales

    $        38,210



    $         2,231



    $     140,438



    $    279,937



       Licensing, royalties and other

    46,302



    19,833



    453,413



    23,046



       Grants

    --



    164,922



    --



    389,380



    Total revenue

    84,512



    186,986



    593,851



    692,363



    Expenses:

















       Cost of sales

    60,619



    98,929



    166,070



    188,792



       Research and development

    87,164



    106,229



    286,789



    572,805



       Selling, general and administrative

    70,747



    107,460



    258,843



    313,709



    Total expenses

    218,530



    312,618



    711,702



    1,075,306



       Loss from operations

    (134,018)



    (125,632)



    (117,851)



    (382,943)



       Interest expense

    (4,236)



    (2,859)



    (12,490)



    (10,299)



       Other income (expense), net

    15,922



    (2,982)



    27,307



    26,912



       Loss before income tax expense (benefit)

    (122,332)



    (131,473)



    (103,034)



    (366,330)



       Income tax expense (benefit)

    (1,032)



    (697)



    3,435



    343



       Net Loss

    $     (121,300)



    $   (130,776)



    $     (106,469)



    $  (366,673)





















       Net loss per share:

















       Basic and diluted 

    $             (0.76)



    $        (1.26)



    $           (0.71)



    $        (3.94)

    Weighted average number of common

    shares outstanding:

      Basic and diluted

    160,049



    103,429



    149,486



    93,046



     

    SELECTED CONSOLIDATED BALANCE SHEET DATA

    (in thousands)





    September 30,

    2024



    December 31,

    2023



    (unaudited)









    Cash and cash equivalents

    $                573,630



    $           568,505



    Marketable securities

    335,901



    --



    Total restricted cash

    14,957



    15,305



    Total current assets

    1,103,680



    1,143,888



    Working capital                                                                 

    (77,319)



    (491,250)



    Total assets

    1,712,483



    1,797,490



    Convertible notes payable

    169,265



    168,016



    Total stockholders' deficit

    (526,436)



    (716,927)



     

    Contacts:

    Investors

    Luis Sanay, CFA

    240-268-2022

    [email protected]

    Media

    Giovanna Chandler

    202-709-5563

    [email protected]

     

    Novavax Logo (PRNewsfoto/Novavax)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-reports-third-quarter-2024-financial-results-and-operational-highlights-302302332.html

    SOURCE Novavax, Inc.

    Get the next $NVAX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVAX

    DatePrice TargetRatingAnalyst
    2/28/2025$19.00Buy
    BTIG Research
    7/30/2024$8.00Neutral → Underweight
    JP Morgan
    5/10/2024$4.00 → $12.00Underperform → Neutral
    BofA Securities
    5/10/2024Underweight → Neutral
    JP Morgan
    8/9/2023$15.00Neutral → Buy
    B. Riley Securities
    4/20/2023$55.00 → $10.00Outperform → Market Perform
    TD Cowen
    3/1/2023$29.00 → $10.00Buy → Neutral
    B. Riley Securities
    1/9/2023$74.00 → $37.00Buy
    B. Riley Securities
    More analyst ratings

    $NVAX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

      FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDASHIELD-Utah study demonstrates that Nuvaxovid® resulted in fewer and less severe reactogenicity symptoms when compared to marketed mRNA vaccine; Nuvaxovid recipients experienced approximately 39% fewer symptoms on averageData presented at World Vaccine Congress showcases Matrix-M® utility when co-administered with a broad array of vaccine platforms and diseasesStrengthened partnership with Takeda in Japan, the third largest pharmaceutical market, with significant improvement in financial termsRaises full year 2025 revenue framework to between $975 mill

      5/8/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax to Participate in BofA Securities 2025 Health Care Conference

      GAITHERSBURG, Md., May 7, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, May 14, 2025 Time: 3:00 – 3:30 p.m. Pacific Time (PT) Location: Las Vegas, NV Conference Event: Investor Meetings Date: Wednesday, May 14, 2025 A webcast of the fireside chat will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcast will be available for 30 days. About NovavaxNovavax, Inc. (NASDAQ:NVAX) tackles some of the world's most significant health challenges by leveraging its scientific expertise in vaccines

      5/7/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan

      Improved financial terms for Novavax and streamlined operations will help both companies better meet the needs of the Japanese market Nuvaxovid®, a protein-based, non-mRNA COVID-19 vaccine, will continue to be available in Japan, the world's third largest pharmaceutical marketGAITHERSBURG, Md., May 5, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) has updated the terms of the previously announced collaboration and licensing agreement (CLA) with Takeda. The improved financial terms of the amended agreement for the development, manufacturing and commercialization of Nuvaxovid® in Japan include an upfront payment, payment related to the 2024/2025 season, annual milestones associated with regu

      5/5/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NVAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

      For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

      9/3/24 2:26:49 PM ET
      $NVAX
      $PFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

      For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

      8/30/24 2:26:48 PM ET
      $NVAX
      $PFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

      For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

      10/3/23 2:56:27 PM ET
      $NVAX
      $PFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $NVAX
    Financials

    Live finance-specific insights

    See more
    • Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

      FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDASHIELD-Utah study demonstrates that Nuvaxovid® resulted in fewer and less severe reactogenicity symptoms when compared to marketed mRNA vaccine; Nuvaxovid recipients experienced approximately 39% fewer symptoms on averageData presented at World Vaccine Congress showcases Matrix-M® utility when co-administered with a broad array of vaccine platforms and diseasesStrengthened partnership with Takeda in Japan, the third largest pharmaceutical market, with significant improvement in financial termsRaises full year 2025 revenue framework to between $975 mill

      5/8/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax to Report First Quarter 2025 Financial Results on May 8, 2025

      GAITHERSBURG, Md., May 1, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its first quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, May 8, 2025. Details of the event and replay are as follows: Conference call details: Date: May 8, 2025 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/43UHjFq Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcast: ir.novavax.com/events Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants

      5/1/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      Transitioned lead commercial responsibility of Nuvaxovid™ COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in the fourth quarter of 2024 and $682 million for the full year 2024 Achieved $50 million milestone under Sanofi agreement associated with the pediatric clinical trial database lock for the first cohortCompleted $200 million sale of Czech Republic manufacturing facility to Novo Nordisk; reduces annual costs by approximately $80 millionAdvanced pipeline programs, based on proven and innovative technology platformEnded full year 2024 with over $1 billion in Cash and accounts receivablesProvides 2025 financial guidance and revenue framew

      2/27/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Novavax Inc.

      SC 13G/A - NOVAVAX INC (0001000694) (Subject)

      11/12/24 4:46:17 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Novavax Inc.

      SC 13G/A - NOVAVAX INC (0001000694) (Subject)

      11/4/24 1:19:04 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Novavax Inc.

      SC 13G/A - NOVAVAX INC (0001000694) (Subject)

      7/10/24 6:16:55 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NVAX
    Leadership Updates

    Live Leadership Updates

    See more
    • Novavax Appoints Charles Newton to Board of Directors

      GAITHERSBURG, Md., April 29, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare investment banking to his role on the Novavax Board of Directors. "Charles brings a wealth of expertise across corporate finance and capital markets to Novavax," said John C. Jacobs, President and Chief Executive Officer, Novavax. "The knowledge he brings to our already experienced board will be invaluable as we continue to execute our corp

      4/29/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brian Rosen, Commercial Strategy Senior Executive, Appointed as Director of Capstone Companies, Inc.

      Capstone Companies, Inc. (OTCQB:CAPC) announced today the appointment of Brian Rosen as a non-employee director, effective January 20, 2025. Mr. Rosen has extensive experience in marketing, business development, contract negotiation and government relations as well as experience as a member of two public companies' management. He served as Senior Vice President, Global Market Access, Public Policy & Alliances (2021 - 2023), Senior Vice President, Commercial Strategy (2018 - 2021) and Vice President, Market Access, Policy, & Government Affairs (2015 - 2017) with Novavax, Inc. (NASDAQ:NVAX). Before Novavax, Inc., Mr. Rosen served as Chief Policy, Advocacy & Patient Services Officer (2014 -

      1/23/25 9:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development

      Ruxandra Draghia-Akli, MD, PhD brings more than 20 years of extensive clinical, corporate and global public health expertise to support Novavax's transition to an R&D-focused organizationDr. Draghia-Akli will be integral in strategically evaluating the Company's pipeline and opportunities for its Matrix-M™ adjuvant and protein-based technology platformGAITHERSBURG, Md., Sept. 25, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Ruxandra Draghia-Akli, MD, PhD, will join the Company in November 2024 as Executive Vice President and Head of Research & Development (R&D). Dr. Draghia-Akli brings m

      9/25/24 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NVAX
    SEC Filings

    See more
    • Novavax Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NOVAVAX INC (0001000694) (Filer)

      5/8/25 8:26:56 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Novavax Inc.

      10-Q - NOVAVAX INC (0001000694) (Filer)

      5/8/25 7:59:11 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - NOVAVAX INC (0001000694) (Filer)

      5/5/25 9:25:23 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Newton Charles W.

      4 - NOVAVAX INC (0001000694) (Issuer)

      4/29/25 8:08:08 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Newton Charles W.

      3 - NOVAVAX INC (0001000694) (Issuer)

      4/29/25 8:06:39 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Shiver John W.

      4 - NOVAVAX INC (0001000694) (Issuer)

      3/12/25 8:04:38 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Novavax with a new price target

      BTIG Research initiated coverage of Novavax with a rating of Buy and set a new price target of $19.00

      2/28/25 7:28:04 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax downgraded by JP Morgan with a new price target

      JP Morgan downgraded Novavax from Neutral to Underweight and set a new price target of $8.00

      7/30/24 6:25:22 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax upgraded by BofA Securities with a new price target

      BofA Securities upgraded Novavax from Underperform to Neutral and set a new price target of $12.00 from $4.00 previously

      5/10/24 1:12:36 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care